Exploring the anticancer potential of Eleutherine bulbosa: A systematic network pharmacology study on lung cancer

Mutiah, Roihatul ORCID: https://orcid.org/0000-0002-8196-9029 and Rachmawati, Ermin ORCID: https://orcid.org/0000-0003-1045-7066 (2024) Exploring the anticancer potential of Eleutherine bulbosa: A systematic network pharmacology study on lung cancer. Journal of Advanced Pharmaceutical Technology & Research, 15 (1). pp. 49-55. ISSN 2231-4040

Preview

Text 18208.pdf - Published Version Download (3MB) | Preview

Abstract

Chemotherapy application in lung cancer patients has several side effects and shows lower effectiveness due to chemoresistance. Although Eleutherine bulbosa (Mill.) Urb. (EBE) elicit anticancer properties, yet the exact profile of its active compounds and lung cancer inhibition mechanisms were not fully understood. This study aimed to identify suggestive compounds from EBE extract and explain the molecular mechanisms of EBE against lung cancer. Identification of the compound from the EBE extract was confirmed using liquid chromatography–tandem mass spectrophotometry (LC–MS/MS). The bioavailability profile of three major metabolites was identified using absorption, distribution, metabolism, excretion, toxicity software. The anticancer molecular mechanism prediction of the drugs was ascertained by network pharmacology using Cytoscape 3.9.1 and the protein–protein interaction network technique with STRING 11.0. Interaction between resveratrol and extracellular growth factor receptor (EGFR) was analyzed using site-specific molecular docking with erlotinib as the control using PyRx Autodock Vina 9.0 and BIOVIA Discovery Studio. A total of 16 active compounds were identified from LC-MS/MS. Only resveratrol showed anticancer properties by its interaction with 13 genes and 6 signaling pathways related to lung cancer. The molecular docking result supports the network pharmacology finding. The binding affinity of resveratrol with EGFR, important receptor in lung cancer, was more negative (−6.9 kcal/mol) than erlotinib (−6.2 kcal/mol) as the control. Evidence suggested that resveratrol in EBE exhibits anticancer effects by modulating lung cancer cell proliferation and apoptosis through EGFR binding.

Item Type:	Journal Article
Keywords:	Eleutherine bulbosa; lung cancer; molecular docking; network pharmacology; resveratrol
Subjects:	11 MEDICAL AND HEALTH SCIENCES > 1101 Medical Biochemistry and Metabolomics > 110106 Medical Biochemistry - Proteins and Peptides (incl. Medical Proteomics)
Divisions:	Faculty of Medical and Health Sciences > Department of Pharmacy
Depositing User:	Dr. M.Kes. Roihatul Muti'ah
Date Deposited:	05 Feb 2024 14:46

Downloads

Origin of downloads

Actions (login required)

View Item